AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 05:02 pm

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

153.2 USD

Average target price

174.6 USD

Spread / Average Target

+13.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.40%	238B
ELI LILLY AND COMPANY	+54.07%	816B
NOVO NORDISK A/S	+38.59%	634B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	323B
ABBVIE INC.	+5.72%	293B
ROCHE HOLDING AG	+0.61%	222B
NOVARTIS AG	+13.24%	218B
AMGEN INC.	+7.42%	167B
PFIZER, INC.	-3.79%	158B

Other Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:11 03/07/2024 BST			5-day change	1st Jan Change
12,020 ^GBX	-0.55%		-4.27%	+13.40%

03:04pm	ASTRAZENECA : Buy rating from Berenberg	ZD
10:58am	Aptamer shares jump as inks agreement with AstraZeneca	AN

ASTRAZENECA : Buy rating from Berenberg	02:04pm	ZD
Aptamer shares jump as inks agreement with AstraZeneca	09:58am	AN
Aptamer Group plc Announces New Agreement with AstraZeneca to Evaluate the Optimer Fibrotic Liver Delivery Vehicles for the Targeted Delivery of SiRNA	07:00am	CI
ASTRAZENECA : Jefferies reaffirms its Neutral rating	07-02	ZD
Deutsche Bank cuts Quilter, ups Polar Capital	07-02	AN
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June	07-01	MT
UK Stocks Flat; Manufacturing Sector Remains in Expansion Zone	07-01	MT
AstraZeneca's Potential Covid-19 Prevention Drug Gets EU Accelerated Assessment	07-01	MT
AstraZeneca's Imfinzi, Lynparza Combination Recommended for Approval in Europe as Endometrial Cancer Treatment	07-01	MT
AstraZeneca applies to the EMA for a Covid antibody	07-01	CF
AstraZeneca: CHMP recommends Imfinzi and Lynparza	07-01	CF
Stocks called higher ahead of Thursday's election	07-01	AN
AstraZeneca's Combination Formulation for Endometrial Cancer Gains Support for EU Application	07-01	MT
AstraZeneca's Application for COVID-19 Prevention Drug Wins Accelerated Review in EU	07-01	MT
AstraZeneca's COVID prevention drug application gets EU fast-track assessment	07-01	RE
AstraZeneca Plc's Lynparza & Imfinzi Announces Positive CHMP in Endometrial	07-01	CI
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06-27	RE
European Equities Close Lower in Wednesday Trading	06-26	MT
ASTRAZENECA : Deutsche Bank sticks Neutral	06-26	ZD
AstraZeneca Says Tagrisso With Chemotherapy Approved in China	06-26	MT
AstraZeneca: Tagrisso approved in China for NSCLC	06-26	CF
AstraZeneca's Tagrisso plus chemo gets approval in China	06-26	AN
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment	06-26	RE
AstraZeneca Wins Chinese Regulatory Nod for Lung Cancer Combination Treatment	06-26	MT
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws	06-25	MT